SCHEMBL5457809

SCHEMBL5457809

NC(=O)c1c(NC(=O)Nc2ccc(Oc3ccccc3)cc2)sc2c1CCOC2

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
NPC1 O15118 1/20 0.55
RAB9A P51151 1/20 0.55
EPHB4 P54760 1/20 0.55
CFTR P13569 1/20 0.54
KCNH2 Q12809 7/20 0.52
TNIK Q9UKE5 1/20 0.51
CXCR2 P25025 3/20 0.51
RAB7A P51149 1/20 0.48
ANO1 Q5XXA6 2/20 0.47
ALDH1A1 P00352 1/20 0.47
LMNA P02545 1/20 0.47
GAA P10253 1/20 0.47
MAPT P10636 1/20 0.47
PTPRC P08575 1/20 0.47
PTPN2 P17706 1/20 0.47
PTPN1 P18031 1/20 0.47
PTPRB P23467 1/20 0.47
PTPRE P23469 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5455947 0.91 MEN1 (0.65) MEN1KMT2ANPC1RAB9AEPHB4
SCHEMBL5460547 0.89 MEN1 (0.58) MEN1KMT2ANPC1RAB9AEPHB4
SCHEMBL5453424 0.88 CFTR (0.59) MEN1KMT2ANPC1RAB9AEPHB4
SCHEMBL5465704 0.88 NPC1 (0.51) MEN1KMT2ANPC1RAB9AEPHB4
SCHEMBL5455976 0.85 KMT2A (0.64) MEN1KMT2ANPC1RAB9ACFTR
SCHEMBL16962264 0.85 KCNH2 (0.68) MEN1KMT2ANPC1RAB9AEPHB4
SCHEMBL5457892 0.85 CFTR (0.56) MEN1KMT2ANPC1RAB9AEPHB4
SCHEMBL5449304 0.84 CFTR (0.65) MEN1KMT2ANPC1RAB9AEPHB4
SCHEMBL5457888 0.84 ANO1 (0.64) MEN1KMT2ANPC1RAB9AEPHB4
SCHEMBL5457822 0.84 CFTR (0.59) MEN1KMT2ANPC1RAB9AEPHB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 MEN1 2891/4885KMT2A 4785/4885NPC1 2627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.